Stock Analysis

Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 30% More Shares

Published
NasdaqCM:VANI

Those following along with Vivani Medical, Inc. (NASDAQ:VANI) will no doubt be intrigued by the recent purchase of shares by Gregg Williams, Independent Chairman of the Board of the company, who spent a stonking US$5.0m on stock at an average price of US$1.26. Not only is that a big swing, but it increased their holding size by 30%, which is definitely great to see.

View our latest analysis for Vivani Medical

The Last 12 Months Of Insider Transactions At Vivani Medical

Notably, that recent purchase by Gregg Williams is the biggest insider purchase of Vivani Medical shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$1.31. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Vivani Medical share holders is that insiders were buying at near the current price.

While Vivani Medical insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqCM:VANI Insider Trading Volume November 16th 2024

Vivani Medical is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Does Vivani Medical Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 34% of Vivani Medical shares, worth about US$27m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At Vivani Medical Tell Us?

The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Vivani Medical shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Vivani Medical. When we did our research, we found 5 warning signs for Vivani Medical (2 are a bit concerning!) that we believe deserve your full attention.

But note: Vivani Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.